The fee to file a new drug application falls by $81,250 next year, because the FDA is holding four and a half weeks more carryover cash than the statute lets it keep

Four and a half weeks. That is the size of the cushion the FDA is carrying above what Congress permits, and it is why the biggest fee in drug regulation is going down next year rather than up.

The agency filed its prescription drug user fee rates for fiscal 2027 on Wednesday morning, and both of the numbers that matter went backwards: an application requiring clinical data will cost $4,600,753 from October 1, against $4,682,003 this year, and the annual program fee charged on each approved product falls to $416,857 from $442,213. Those are rare directions for a federal fee schedule. Neither reflects any judgment that drug review is getting cheaper to do. The statute did it.

Every input in the calculation rose. Personnel compensation and benefits per full-time equivalent at FDA went from $183,486 in 2023 to $202,515 in 2025, a three-year average increase of 5.7330 percent, which fed an inflation adjustment of $71,542,514 on a statutory base of $1,515,410,160. Strategic hiring and retention added $4,000,000. Additional direct costs added $41,505,100. The capacity planning adjustment came to zero.

Then the statute took money back.

Section 736(c)(4) of the Federal Food, Drug, and Cosmetic Act sets a band rather than a target. If FDA holds less than 10 weeks of carryover user fees, it must raise fees to get back inside. If it holds more than 14 weeks, it must cut them. The agency computes a week by taking the adjusted revenue figure of $1,592,267,294 and dividing by 52, which puts one week of operations at $30,620,525 and the 14-week ceiling at $428,687,350.

FDA assessed its reserves at the end of June and forecast the fourth quarter, and estimates it will finish fiscal 2026 holding $564,378,337, which it states equals 18.43 weeks. That is $135.7m above the ceiling, and the statute requires the excess to come out of next year's fees. The operating reserve adjustment is recorded as negative $135,690,987, and it is nearly twice the size of the inflation increase it cancels.

One footnote is worth reading, because it makes the reserve smaller than it first appears. FDA excludes $78,850,995 of user fees collected before 2010 from the calculation entirely, on the ground that the money is held by the agency but unavailable for obligation for want of an appropriation. Sixteen years of an unspendable balance sitting outside the arithmetic is the sort of detail that only surfaces in a fee notice.

The generic side went the other way. Under the Generic Drug User Fee Amendments, a separate statute with its own revenue mechanics, the abbreviated new drug application fee rises to $375,684 from $358,247, and the drug master file fee to $109,899 from $102,584. Facility fees fell: a domestic finished dosage form facility pays $230,033 against $238,943. Brand and generic fees are set in different sections of the same act and there is no reason they should move together, which is the answer to the obvious question about why one schedule went up on the same morning the other went down.

Comments are not invited. Fee notices announce arithmetic the statute already specified, and the rates take effect on October 1 whatever anybody thinks of them.